cyclooxygenase

(redirected from Cyclo-oxygenase)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to Cyclo-oxygenase: Cyclooxygenase 2 inhibitors

cyclooxygenase

[‚sī·klō′äks·ə·jə‚nās]
(biochemistry)
An enzyme that catalyzes the conversion of arachidonic acid into prostaglandins.
Mentioned in ?
References in periodicals archive ?
Since, as far as is known, indomethacin is not an inhibitor of lipoxygenase, it is highly possible that cyclo-oxygenase was involved in the above-mentioned conversion of arachidonic acid to prostaglandins and a thromboxane.
The researchers also claimed to have shown the involvement of cyclo-oxygenase, although they had not studied the effect of cyclo-oxygenase inhibitors on the corn leaf homogenates.
At least two of the inhibitors used - namely, aspirin and indomethacin - are known inhibitors of the enzyme cyclo-oxygenase.
There are, however, interesting reports that ascosporogenesis (sexual stage) of the yeast Dipodascopsis is seriously repressed by cyclo-oxygenase inhibitors (aspirin and indomethacin).
The inhibition of ADP-induced platelet aggregation is linked with the inhibition of the cyclo-oxygenase pathway also involved in the inflammatory mechanism, through the formation of arachidonic acid and thromboxane A2.
Acetylsalicylic acid (used as positive control agent at 1 mg/ml saline) inhibits the platelet function by acetylation of the platelet cyclo-oxygenase.
Americana stem barks also displayed activity in the ADP inhibition test (Table 1), thus suggesting a possible anti-inflammatory activity related to the cyclo-oxygenase inhibition.
Stansfield says that Deramaxx selective properties have been scientifically demonstrated by using cloned canine cyclo-oxygenase during in vitro studies.
Pfizer is co-developing valdecoxib, a second-generation cyclo-oxygenase 2 (COX-2) inhibitor for the treatment of osteoarthritis, rheumatoid arthritis and pain, with Pharmacia Corporation, which is scheduled to file an NDA for the drug near the end of this year, Dr.
In general, both the therapeutic benefits and gastrotoxicity of NSAIDs have been linked to the inhibition of the cyclo-oxygenase (COX) enzyme.
But experts sharply disagree on whether the findings on this latest addition to the class of selective cyclo-oxygenase 2 (COX-2) inhibitors truly exonerate the coxib of its role in potentiating myocardial infarctions and gastrointestinal adverse effects.
She has been responsible for the clinical development of a number of compounds including a cyclo-oxygenase inhibitor, leukotriene antagonist, beta 2 agonist, an anti-IgE monoclonal antibody and hormone replacement therapy.